Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A highly sensitive and specific radioimmunoassay for
LRF
was applied to the measurement of endogenous
LRF
in various hypothalamic extracts. Specific antiserum was obtained by injecting
LRF
conjugated to human serum albumin with glutaraldehyde. Thyrotropin-releasing hormone, lysine vasopressin,
oxytocin
, noradrenaline, LH, FSH and cortical extracts did not appear to affect the assay, and the maximum cross-reaction observed with the
LRF
analogs tested was 8.5 p. 100 with
LRF
2-10. The best detection limit (0.4 pg/tube) was usually obtained when the labelled
LRF
had been purified by polyacrylamide gel electrophoresis. Within and between-assay coefficients of variation were 8.0 and 12.6 p. 100, respectively (from B/Bo = 20 to 80 p. 100). Synthetic
LRF
administered to rams by intravenous injection was readily detectable in the peripheral plasma. However, the direct measurement of plasma endogenous
LRF
may give misleading results due to non-specific interference by plasma factors. No endogenous
LRF
could be detected in plasma methanol or acetone extracts obtained from rats and rams in various physiological conditions. The inhibition curves parallel to the synthetic
LRF
curve were obtained by diluting the crude hypothalamic extracts of rams and rats, and a good correlation (r = 0.997) with the Ramirez-McCann bioassay resulted, indicating that using radioimmunoassay to determine hypothalamic
LRF
content may be fruitful in studying hypothalamo-pituitary gonad interactions. The
LRF
content of rat and ovine hypothalami ranged from 2-8 to 20-80 ng of
LRF
, respectively.
...
PMID:Reassessment of LRF radioimmunoassay in the plasma and hypothalamic extracts of rats and rams. 676 Feb 82